Historial de carrera de Todd C. Zankel
Antiguos cargos conocidos de Todd C. Zankel.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Director Técnico/Científico/I+D | 01/10/2009 | 01/10/2009 |
| Fundador | 01/10/2009 | 01/10/2009 | |
| BIOMARIN PHARMACEUTICAL INC. | Director Técnico/Científico/I+D | 01/01/1997 | 01/01/2005 |
| RAPTOR PHARMACEUTICAL CORP | Fundador | 29/09/2009 | - |
| Raptor Pharmaceutical, Inc. | Director Técnico/Científico/I+D | 01/01/2006 | - |
| Fundador | 24/11/2010 | - |
Formación de Todd C. Zankel.
| The Reed Institute | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 7 |
Operativa
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 3 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
| Raptor Pharmaceutical, Inc. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
- Bolsa de valores
- Insiders
- Todd C. Zankel
- Experiencia
